BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26995528)

  • 1. Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold.
    Nishiguchi GA; Burger MT; Han W; Lan J; Atallah G; Tamez V; Lindvall M; Bellamacina C; Garcia P; Feucht P; Zavorotinskaya T; Dai Y; Wong K
    Bioorg Med Chem Lett; 2016 May; 26(9):2328-32. PubMed ID: 26995528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
    Wang HL; Cee VJ; Chavez F; Lanman BA; Reed AB; Wu B; Guerrero N; Lipford JR; Sastri C; Winston J; Andrews KL; Huang X; Lee MR; Mohr C; Xu Y; Zhou Y; Tasker AS
    Bioorg Med Chem Lett; 2015 Feb; 25(4):834-40. PubMed ID: 25597005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
    Burger MT; Nishiguchi G; Han W; Lan J; Simmons R; Atallah G; Ding Y; Tamez V; Zhang Y; Mathur M; Muller K; Bellamacina C; Lindvall MK; Zang R; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Basham S; Chan J; Ginn E; Aycinena A; Holash J; Castillo J; Langowski JL; Wang Y; Chen MY; Lambert A; Fritsch C; Kauffmann A; Pfister E; Vanasse KG; Garcia PD
    J Med Chem; 2015 Nov; 58(21):8373-86. PubMed ID: 26505898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
    Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
    Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
    Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
    Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of pyrrolo[2,3-g]indazoles as new Pim kinase inhibitors.
    Gavara L; Suchaud V; Nauton L; Théry V; Anizon F; Moreau P
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2298-301. PubMed ID: 23499503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of low-nanomolar PIM kinase inhibitors.
    Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
    Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
    Bataille CJ; Brennan MB; Byrne S; Davies SG; Durbin M; Fedorov O; Huber KV; Jones AM; Knapp S; Liu G; Nadali A; Quevedo CE; Russell AJ; Walker RG; Westwood R; Wynne GM
    Bioorg Med Chem; 2017 May; 25(9):2657-2665. PubMed ID: 28341403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
    Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
    Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
    Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
    Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
    J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
    Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pim kinases in hematological malignancies: where are we now and where are we going?
    Mondello P; Cuzzocrea S; Mian M
    J Hematol Oncol; 2014 Dec; 7():95. PubMed ID: 25491234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
    Hu H; Wang X; Chan GK; Chang JH; Do S; Drummond J; Ebens A; Lee W; Ly J; Lyssikatos JP; Murray J; Moffat JG; Chao Q; Tsui V; Wallweber H; Kolesnikov A
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5258-64. PubMed ID: 26459208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
    Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
    ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
    Akué-Gédu R; Rossignol E; Azzaro S; Knapp S; Filippakopoulos P; Bullock AN; Bain J; Cohen P; Prudhomme M; Anizon F; Moreau P
    J Med Chem; 2009 Oct; 52(20):6369-81. PubMed ID: 19788246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors.
    Wurz RP; Pettus LH; Jackson C; Wu B; Wang HL; Herberich B; Cee V; Lanman BA; Reed AB; Chavez F; Nixey T; Laszlo J; Wang P; Nguyen Y; Sastri C; Guerrero N; Winston J; Lipford JR; Lee MR; Andrews KL; Mohr C; Xu Y; Zhou Y; Reid DL; Tasker AS
    Bioorg Med Chem Lett; 2015 Feb; 25(4):847-55. PubMed ID: 25599837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.